Clinical Trials Logo

Hepatitis C Viral clinical trials

View clinical trials related to Hepatitis C Viral.

Filter by:
  • None
  • Page 1

NCT ID: NCT03682549 Completed - Hepatitis C Viral Clinical Trials

Oral Microbiome of Patients With Hepatitis C Virus Infection

Start date: December 1, 2019
Phase:
Study type: Observational

Hepatitis C virus (HCV) infection is very common in Egypt and the middle east. The disease affects multiple body organs and may proceed to hepatocellular carcinoma. The viral disease causes changes in the microbial symbiosis in the human body. Thus, the analysis of the microbiome may provide a means of diagnosis for HCV infection. Thus, this study will be held to detect if the microbiome of patients having HCV differ from that of normal individuals.

NCT ID: NCT03356405 Active, not recruiting - Hepatitis C Viral Clinical Trials

Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV

ERAPID HCV
Start date: April 1, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to conduct an evaluation of hepatitis C treatments in NHS Tayside in order to empirically test the "treatment as prevention" models. This will be done by analysing the records of patients who have been tested and treated for hepatitis C using NHS Tayside databases. There will be no interventions carried out as part of this study.

NCT ID: NCT03144635 Completed - Clinical trials for Chronic Kidney Disease stage3

A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

Start date: April 1, 2017
Phase: Phase 4
Study type: Interventional

The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may safely be used for the elderly patients with renal dysfunction. Grazoprevir and elbasvir are metabolized in the liver and do not require dose-adjustment for patients with renal dysfunction. However, no data related to efficacy and safety of the grazoprevir plus elbasvir treatment for Japanese elderly patients with renal dysfunction (eGFR<60 mL/min/1.73m2) have been reported. Therefore, physicians are at a loss whether or not to treat the patients with renal dysfunction due to no evidence. The aim of this study is to investigate the improvement of serum endostatin level of Japanese patients with CKD stage 3 after grazoprevir (NS3/4A protease inhibitor) plus elbasvir (NS5A replication complex inhibitor) treatment by a prospective, multicenter cohort study.